Advertisement

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  • Michael Benatar
Chapter

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired demyelinating neuropathy in which motor symptoms generally predominate over sensory symptoms and large fiber sensory dysfunction is more common than small fiber loss. The course may either be relapsing and remitting or chronically progressive. CIDP may occur in isolation or in the context of a number of systemic disorders, including HIV and hepatitis C infection, inflammatory bowel disease, lymphoproliferative disorders and osteosclerotic myeloma. The importance of distinguishing CIDP from among other causes of peripheral neuropathy lies in the observation that a significant proportion of patients with CIDP may respond to immune-modifying therapy. In this chapter, we consider important diagnostic questions that relate to the optimal electrophysiological criteria that should be used to define the disorder and the relative diagnostic utility of sural nerve biopsy. Many different forms of immunosuppressive therapy have been proposed for the treatment of CIDP, and although some of these therapeutic modalities have been studied in randomized controlled trials, many have not. We shall also consider the evidence supporting the use of these various immunosuppressive agents as well as the prognosis for patients who are treated in this manner.

Keywords

Compound Muscle Action Potential Motor Neuron Disease Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyradiculoneuropathy Sensory Nerve Action Potential 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435–451.CrossRefPubMedGoogle Scholar
  2. 2.
    Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617–618.Google Scholar
  3. 3.
    Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992;42:1157–1163.CrossRefPubMedGoogle Scholar
  4. 4.
    Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878–884.CrossRefPubMedGoogle Scholar
  5. 5.
    Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195–201.CrossRefPubMedGoogle Scholar
  6. 6.
    Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004;29:565–574.CrossRefPubMedGoogle Scholar
  7. 7.
    Nicolas G, Maisonobe T, Le Forestier N, Leger J-M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002;25:26–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Haq RU, Fries TJ, Pendlebury WW, Kenny MJ, Badger GJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy. A study of proposed electrodiagnostic and histologic criteria. Arch Neurol 2000;57:1745–1750.CrossRefPubMedGoogle Scholar
  9. 9.
    Molenaar DS, Vermuelen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998;64:84–89.CrossRefPubMedGoogle Scholar
  10. 10.
    Dyck P, O’Brien P, Oviatt K, Dinapoli R, Daube J, Barleston J. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136–141.CrossRefPubMedGoogle Scholar
  11. 11.
    Mehndiratta M, Hughes R. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Systematic Reviews 2004;2:CD002062.Google Scholar
  12. 12.
    Dalakas M Engel W. Chronic relapsing dysimmune polyneuropathy pathogenesis and treatment. Ann Neurol 1981;9Suppl134–134Google Scholar
  13. 13.
    McCombe P, Pollard J, McLeod J. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110:1617–1630.CrossRefPubMedGoogle Scholar
  14. 14.
    Hahn A, Bolton C, Zochodne D, Feasby T. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067–1077.CrossRefPubMedGoogle Scholar
  15. 15.
    Mendell J, Barohn R, Freimer M, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445–449.CrossRefPubMedGoogle Scholar
  16. 16.
    Thompson N, Choudhary P, Hughes R, Quinlivan R. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243:280–285.CrossRefPubMedGoogle Scholar
  17. 17.
    Vermeulen M, van Doorn P, Brand A, Strengers P, Jennekens F, Busch H. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1993;56:36–39.CrossRefPubMedGoogle Scholar
  18. 18.
    Dyck P, Litchy W, Kratz K, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838–845.CrossRefPubMedGoogle Scholar
  19. 19.
    Van Schaik I, Winer J, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Systematic Reviews 2004;2:CD001797.Google Scholar
  20. 20.
    Dyck P, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–465.CrossRefPubMedGoogle Scholar
  21. 21.
    Hahn A, Bolton C, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055–1066.CrossRefPubMedGoogle Scholar
  22. 22.
    Hughes R, Swan A, van Doorn P. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Systematic Reviews 2004;2:CD003280.Google Scholar
  23. 23.
    Dyck P, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35.Google Scholar
  24. 24.
    Hadden R, Sharrack B, Bensa S, Soudain S, Hughes R. Randomized trial of interferon-beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57–61.CrossRefPubMedGoogle Scholar
  25. 25.
    Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000;21:31–37.CrossRefPubMedGoogle Scholar
  26. 26.
    Choudhary P, Hughes R. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 1995;88:493–502.PubMedGoogle Scholar
  27. 27.
    Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321–328.CrossRefPubMedGoogle Scholar
  28. 28.
    Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359–368.CrossRefPubMedGoogle Scholar
  29. 29.
    Saperstein DS, Katz JJ, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311–324.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Michael Benatar
    • 1
  1. 1.Department of NeurologyEmory University School of MedicineAtlanta

Personalised recommendations